Please enter exact key words


One-stop solution for early-stage drug projects

As a thriving pharmaceutical company, Protheragen Inc. (“Protheragen”) focuses on acquiring, developing and commercializing novel pharmaceutical and biotechnology products for both therapeutic purposes and diagnostic applications. Guided by our advanced business strategy – the “VIC R&D model”: V (risk investment), I (IP right) and C (CRO), we are dedicated to making drug discovery and development activities the most effective via a collection of efforts and advantages from all agencies. At the same time, Protheragen has several subsidiaries, also known as Protheragen, such as PSR Biopharma [], Alpha Bioventure []. These subsidiaries can help in-licenses, out- licenses, develop and commercialize products or programs.

Protheragen now has a number of on-going, internal development programs that seek for innovative cancer immunotherapies. Aiming high, we also use our pharmaceutical and biotechnology business expertise as well as drug development capabilities to provide funding and management services to help our partners achieve their goals. Protheragen believes brotherhood means more than sole competition.

Protheragen’s therapeutic field is widely extended, which gives us maximum flexibility and enables us to devote ourselves to the discovery and development of new technologies with abundant clinical and commercial potential. We welcome all project owners to contact us for further discussion and cooperation!

Our streamlined management structure and rich trading experience allow us to seize opportunities that may elapse in a second and enable us to select from a series of options the best corporate or financial structure so as to successfully develop each product candidate. We believe drug development surely will be accelerated by combining Protheragen’s skills and expertise.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118

Opening Hours

Monday — Sunday: 9am — 6pm